FibroBiologics to Present at the BIO International Convention 2024

FibroBiologics to Present at the BIO International Convention 2024

Written by Customer Service on . Posted in Public Companies.

HOUSTON, May 07, 2024 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present a corporate update on recent business and clinical developments at the 2024 BIO International Convention, June 3-6, 2024, in San Diego, California. The presentation will occur on Tuesday, June 4, 2024, at 11:45 a.m. PDT in Theater 3.

“Since presenting at the BIO International Convention last year, FibroBiologics has made tremendous progress as a company. This will be the first year we present at the conference as a public company after a successful direct listing in January,” said Pete O’Heeron. “We are thrilled to showcase our latest advancements and the potential of our fibroblast-based therapies in multiple indications. This is a pivotal time for us, and we eagerly anticipate discussing our innovative approaches, discoveries and proprietary cell therapies with our peers forging new collaborations and pathways in biotech.”

To schedule a meeting at the BIO International Convention with FibroBiologics, please submit a meeting request through the BIO One-on-One Partnering™ platform. For more information, please visit FibroBiologics’ website or email FibroBiologics at info@fibrobiologics.com.

About FibroBiologics

Based in Houston, FibroBiologics is a cell therapy and regenerative medicine company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 150+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
212-845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.